肝细胞癌（HCC）恶性程度高,进展迅速,预后差,目前在全球及我国都处于高发地位。PI3K-AKT-mTOR 信号通路是细胞内最常见的信号传导途径,也是人类癌症中最常见的活化途径。目前已发现多个因子通过PI3K-AKT-mTOR 信号通路参与肝细胞癌的发生发展,该通路的相关蛋白可能成为HCC治疗的潜在靶点。因此,阐明PI3K-AKT-mTOR信号通路的上游调控信号及调控网络,将为临床诊断和治疗HCC提供新的方向和理论基础。

PI3K-AKT-mTOR信号通路；肝细胞癌（HCC）

[1] Latest global cancer data: Cancer burden rises to 19.3 million new cases and 10.0 million cancer deaths in 2020. IARC.2020. [2] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018,68(6):394-424. [3] Zeng H, Chen W, Zheng R, Zhang S, Ji JS, Zou X, Xia C, Sun K, Yang Z, Li H, Wang N, Han R, Liu S, Li H, Mu H, He Y, Xu Y, Fu Z, Zhou Y, Jiang J, Yang Y, Chen J, Wei K, Fan D, Wang J, Fu F, Zhao D, Song G, Chen J, Jiang C, Zhou X, Gu X, Jin F, Li Q, Li Y, Wu T, Yan C, Dong J, Hua Z, Baade P, Bray F, Jemal A, Yu XQ, He J. Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries. Lancet Glob Health, 2018,6(5): e555-e567. [4] Singal AG, Yopp A, S Skinner C, Packer M, Lee WM, Tiro JA. Utilization of hepatocellular carcinoma surveillance among American patients: a systematic review.Gen Intern Med, 2012 ,27(7):861-7. [5] S M L ,Petar S ,H C M , et al. Discovery and saturation analysis of cancer genes across 21 tumour types.Nature, 2014,505(7484):495-501. [6]徐聪聪,陈浩.PI3K/Akt/mTOR信号通路在皮肤鳞状细胞癌中的研究进展.中华皮肤科杂志, 2022, 55(3):4. [7] Fruman DA et al. The PI3K pathway in human disease.Cell, 2017,170, 605–635. [8] Camillo,Porta,Chiara,et al.Targeting PI3K/Akt/mTOR Signaling in Cancer[J].Frontiers in Oncology, 2014, 4(4):64. [9] Matter MS, Decaens T, Andersen JB, Thorgeirsson SS. Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends. J Hepatol, 2014,60:855–65. [10]Rui Z ,Yuzhen G ,Yongjun G , et al. NAP1L5 targeting combined with MYH9 Inhibit HCC progression through PI3K/AKT/mTOR signaling pathway. Aging, 2022, 14 [11]Manning BD, Toker A.AKT/PKB Signaling: Navigating the Network.Cell, 2017,169:381–405. [12]Vicente-Manzanares M, Ma X, Adelstein RS, Horwitz AR. Non-muscle myosin II takes centre stage in cell adhesion and migration. Nat Rev Mol Cell Biol, 2009,10:778–90. [13]Lin X, Li AM, Li YH, Luo RC, Zou YJ, Liu YY, Liu C, Xie YY, Zuo S, Liu Z, Liu Z, Fang WY. Silencing MYH9 blocks HBx-induced GSK3βubiquitination and degradation to inhibit tumor stemness in hepatocellular carcinoma. Signal Transduct Target Ther, 2020,5:13. [14]Lin X, Yu GF, Zuo S, Luo RC, Fang WY. Low MYH9 expression predicts a good prognosis for hepatocellular carcinoma. Int J Clin Exp Pathol, 2018,11:2784–91. [15]Fen Lin,Wei Yan,Gang Song,Wen Ting,Tianhui Hu,Guoyang Wu. Metformin targets liver tumor-initiating cells through the PI3K-AKT-m TOR survival pathway[J]. Chinese Science Bulletin, 2014,5928:675-88. [16]Fu HangWei , Lin Xia , Zhu YuanXin , Lan Xiang , Kuang Yi , Wang YuZhou , Ke ZhiGang , Yuan Tao , Chen Ping.Circ-IGF1R has pro-proliferative and anti-apoptotic effects in HCC by activating the PI3K/AKT pathway.GENE, 2019,716:144031 [17]Zhang, J., Zhi, X., Shi, S., Tao, R., Chen, P., Sun, S., Bian, L., Xu, Z., Ma, L. SPOCK1 is up-regulated and promotes tumor growth via the PI3K/AKT signaling pathway in colorectal cancer. Biochem. Biophys. Res. Commun, 2017,482:870–876. [18]Thomas, S., Quinn, B.A., Das, S.K., Dash, R., Emdad, L., Dasgupta, S., Wang, X.Y., Dent, P.,Reed, J.C., Pellecchia, M., Sarkar, D., Fisher, P.B., Targeting the Bcl-2 family for cancer therapy. Expert Opin. Ther. Targets, 2013,17:61–75. [19]Pepino Y M ,Kuda O ,Samovski D , et al. Structure-Function of CD36 and Importance of Fatty Acid Signal Transduction in Fat Metabolism. Annual Review of Nutrition, 2014, 34 (1): 281-303. [20]Serena M D ,Andrea R ,Giorgia M , et al. Aberrant Metabolism in Hepatocellular Carcinoma Provides Diagnostic and Therapeutic Opportunities.Oxidative medicine and cellular longevity, 2018, 2018:7512159. [21]Nergiz-Unal, R. et al. Basi hepatic cholesterol synthesis and lipoprotein levels impaired by dietary fructose and saturated fatty acids in mice: insight on PCSK9 and CD36. Nutrition, 2020,79-80 110954–110962. [22]Xiaoqing L ,Enze Z ,Li W , et al.The fatty acid receptor CD36 promotes HCC progression through activating Src/PI3K/AKT axis-dependent aerobic glycolysis.Cell Death Disease, 2021,12(4):328-328. [23]Yang P ,Su C ,Luo X , et al.Dietary oleic acid-induced CD36 promotes cervical cancer cell growth and metastasis via up-regulation Src/ERK pathway.Cancer Letters, 2018,438:76-85. [24]Yonghe L ,Yaolin Y ,Yi H , et al.SOS1 regulates HCC cell epithelial-mesenchymal transition via the PI3K/AKT/mTOR pathway.Biochemical and Biophysical Research Communications, 2022,637:161-169. [25]Ai–Wu Ke,Guo–Ming Shi, Zhou J ,et al.CD151 Amplifies Signaling by Integrin α6β1 to PI3K and Induces the Epithelial–Mesenchymal Transition in HCC Cells.Gastroenterology, 2011, 140(5):1629-1641.e15. [26]Shao-Lai Z ,Zhi D ,Zheng-Jun Z , et al. Overexpression of CXCL5 mediates neutrophil infiltration and indicates poor prognosis for hepatocellular carcinoma. Hepatology (Baltimore, Md.), 2012, 56 (6): 2242-54. [27]Zhou S L , Zhou Z J , Hu Z Q ,et al.CXCR2/CXCL5 axis contributes to epithelial–mesenchymal transition of HCC cells through activating PI3K/Akt/GSK-3β/Snail signaling.Cancer Letters, 2015, 358(2):124-135. [28]Dian M J , Li J , Zhang X L ,et al.MST4 negatively regulates the EMT, invasion and metastasis of HCC cells by inactivating PI3K/AKT/Snail1 axis.Journal of Cancer, 2021, 12(15):4463-4477. [29]Sapio L , Salzillo A , Ragone A ,et al.Targeting CREB in Cancer Therapy: A Key Candidate or One of Many? An Update.Cancers, 2020, 12(11):3166. [30]Shaojie Y ,Liwei P ,Wanlin D , et al. Role of Forkhead Box O Proteins in Hepatocellular Carcinoma Biology and Progression (Review).Frontiers in Oncology, 2021,11 667730-667730. [31]Tianxiu D ,Yu Z ,Yaodong C , et al. FOXO1 inhibits the invasion and metastasis of hepatocellular carcinoma by reversing ZEB2-induced epithelial-mesenchymal transition. [J]. Oncotarget, 2017, 8 (1): 1703-1713. [32]D J H ,L J G ,S M B . SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. The Journal of Clinical Investigation, 2002,109(9):1125-1131. [33]Kim J, Kundu M, Viollet B, Guan KL. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol, 2011; 13:132–41. [34]Alers S, Löffler AS, Wesselborg S, Stork B. Role of AMPK-mTOR-Ulk1/2 in the regulation of autophagy:cross talk, shortcuts, and feedbacks. Mol Cell Biol, 2012; 32:2–11. [35]Kui X, Wang Y, Zhang C, Li H, Li Q, Ke Y, Wang L. Prognostic value of SH3PXD2B (Tks4) in human hepatocellular carcinoma: a combined multi-omics andexperimental study. BMC Med Genomics, 2021,14(1):115. [36]Wang J, Zhou Y, Li D, Sun X, Deng Y, Zhao Q. TSPAN31 is a critical regulator on transduction of survival and apoptotic signals in hepatocellular carcinoma cells.FEBS Lett, 2017, 591:2905–18.

2022年云南省教育厅科学研究基金教师类项目（面上项目）：《TKS4影响肝细胞肝癌发生发展的分子机制研究（基金号：2022J0219）》 。 昆明医科大学第二附属医院对外合作研究项目：(项目编号：2022dwhz13)。 昆明医科大学第二附属医院“人才梯队建设”培养项目,(项目编号：RCTDXK-202301)。）

DOI： https://doi.org/10.62639/sspis01.20240102

Published： 2024